Xenetic Biosciences (XBIO)
(Delayed Data from NSDQ)
$3.90 USD
-0.15 (-3.62%)
Updated May 10, 2024 03:49 PM ET
After-Market: $3.85 -0.05 (-1.17%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Xenetic Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 3 | 2 | 1 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 3 | 2 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 7 | 8 | 7 | 14 | 13 |
Income After Depreciation & Amortization | -5 | -7 | -6 | -14 | -13 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -4 | -7 | -6 | -14 | -13 |
Income Taxes | 0 | 0 | 0 | -3 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -4 | -7 | -6 | -11 | -13 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -4 | -7 | -6 | -11 | -13 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -5 | -7 | -6 | -5 | -10 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 9 | 3 |
Income After Depreciation & Amortization | -5 | -7 | -6 | -14 | -13 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.53 | 1.42 | NA | 0.64 | 0.29 |
Diluted EPS Before Non-Recurring Items | -2.71 | -4.60 | NA | -2.30 | -63.30 |
Diluted Net EPS (GAAP) | -2.71 | -4.60 | -5.50 | -17.00 | -63.30 |
Fiscal Year end for Xenetic Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.67 | 0.61 | 0.65 | 0.61 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.67 | 0.61 | 0.65 | 0.61 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.93 | 1.76 | 1.85 | 1.53 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.26 | -1.15 | -1.20 | -0.92 |
Non-Operating Income | NA | 0.08 | 0.09 | 0.15 | 0.06 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -1.17 | -1.06 | -1.05 | -0.86 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.17 | -1.06 | -1.05 | -0.86 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.17 | -1.06 | -1.05 | -0.86 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 1.53 | 1.53 | 1.53 | 1.52 |
Diluted EPS Before Non-Recurring Items | NA | -0.77 | -0.69 | -0.69 | -0.60 |
Diluted Net EPS (GAAP) | NA | -0.73 | -0.69 | -0.69 | -0.60 |